Osteoporosis treatment has expanded well beyond a single pill-a-day approach. Today it involves a growing toolkit of drugs that either slow bone breakdown, stimulate new bone growth, or do both at once, along with decisions about which therapy to use first, how long to stay on it, and what to switch to afterward. The choice depends on how severe your bone loss is, what’s causing it, and how high your fracture risk has become. Getting the sequencing right turns out to matter almost as much as picking the right drug.
Why Bones Weaken in the First Place
Bone is not a static scaffold. Your skeleton constantly tears itself down and rebuilds through a process called remodeling. Cells called osteoclasts dissolve old or damaged bone, and cells called osteoblasts lay down new bone in its place. In healthy adults, the two sides stay roughly in balance. Osteoporosis develops when resorption outpaces formation, whether because of estrogen loss after menopause, aging, medications like glucocorticoids, or other underlying conditions.
A key signaling system keeps resorption in check. Osteoblasts produce a protein called RANKL, which drives osteoclast formation and survival, and another protein called OPG, which acts as a decoy to intercept RANKL before it can activate osteoclasts. The relative concentration of these two proteins is a major determinant of bone mass and strength.1PubMed Central. Functions of RANKL/RANK/OPG in bone modeling and remodeling Most osteoporosis drugs target some part of this balance, either dialing down resorption, boosting formation, or both.
Drugs That Slow Bone Breakdown
The oldest and still most widely prescribed osteoporosis drugs are bisphosphonates, a class that includes alendronate, risedronate, ibandronate, and zoledronic acid. Bisphosphonates bind to bone mineral and are taken up by osteoclasts during resorption, poisoning the cells and slowing the rate at which bone is dissolved. They have proven ability to prevent bone loss and reduce fractures in both postmenopausal women and men with established osteoporosis.2The Journal of Clinical Endocrinology & Metabolism. Benefits and Risks of Bisphosphonate Therapy for Osteoporosis Oral versions are typically taken weekly or monthly, while zoledronic acid is given as an intravenous infusion once a year.
Denosumab works differently. It is a lab-made antibody that targets RANKL directly, blocking the signal that tells osteoclasts to form and survive. Given as an injection every six months, denosumab increases bone density at the spine, hip, and other sites.3PubMed. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys Because it does not embed in bone the way bisphosphonates do, its effects are fully reversible, which creates a specific problem discussed below.
Drugs That Build New Bone
Antiresorptive drugs can preserve what you have, but they don’t create much new bone. For people at very high fracture risk, a different strategy makes more sense: anabolic (bone-building) therapy. Two drugs in this category, teriparatide and abaloparatide, work through the parathyroid hormone receptor. They ramp up bone remodeling but tilt the balance so that formation outpaces resorption, producing a net gain in bone mass.4PubMed Central. Anabolic therapy for osteoporosis: update on efficacy and safety
Both teriparatide and abaloparatide are daily injections given for up to about two years. They provide rapid protection against vertebral and nonvertebral fractures, often within 18 to 19 months, and improve bone density at the spine and hip.5Current Opinion in Endocrine and Metabolic Research. Reviews Parathyroid hormone and abaloparatide treatment for osteoporosis Because the gains can fade once the drug is stopped, anabolic therapy is almost always followed by an antiresorptive to lock in the new bone.
Romosozumab and Dual-Action Treatment
Romosozumab targets a protein called sclerostin, which normally acts as a brake on bone formation. By blocking sclerostin, romosozumab does something no earlier drug accomplished: it simultaneously increases bone formation and decreases bone resorption, at least during the first months of treatment.6PubMed Central. Anti-Sclerostin Antibodies in Osteoporosis and Other Bone Diseases This uncoupling produces large and rapid gains in bone density at the spine, total hip, and femoral neck.7PubMed. Romosozumab in Postmenopausal Women with Low Bone Mineral Density
Romosozumab is given as a monthly injection for 12 months. After that year, you transition to an antiresorptive. The formation-boosting effect is transient; bone formation markers rise early and then fade, while the drop in resorption markers is sustained.8PubMed. Romosozumab: A first-in-class sclerostin inhibitor for osteoporosis This means the drug’s unique dual action has a limited window, making timely follow-up therapy essential. Romosozumab carries a cardiovascular warning and is generally reserved for patients at very high fracture risk who do not have recent heart attack or stroke history.
Hormonal and Selective Options
Hormone replacement therapy (HRT) remains effective at preserving bone in postmenopausal women, but concerns about breast cancer, stroke, and blood clots have limited its use specifically for osteoporosis. Raloxifene offers a middle path. It is a selective estrogen receptor modulator that mimics estrogen’s protective effects on bone while avoiding stimulation of breast or uterine tissue.9PubMed. Raloxifene: a review of its use in postmenopausal osteoporosis
Raloxifene increases bone density at the spine and hip, though the gains tend to be more modest than those seen with HRT. In one head-to-head comparison, low-dose HRT increased lumbar spine bone density by about 5.8% over 12 months, compared with about 2.3% for raloxifene, while hip gains were closer between the two.10PubMed. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis Raloxifene is primarily used to reduce vertebral fractures and is sometimes chosen for women who also want the drug’s associated reduction in invasive breast cancer risk. It does increase the chance of blood clots, so it is not appropriate for everyone.
Why Treatment Order Matters
One of the biggest shifts in osteoporosis management over the past decade is the recognition that the sequence of therapies can be just as important as which drug you take. Starting with an anabolic drug and then switching to an antiresorptive generally produces larger and more lasting gains in bone density than doing it the other way around. Evidence increasingly favors starting anabolic treatment first for people at very high fracture risk, then transitioning to an antiresorptive to maintain the new bone.11PubMed Central. Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy Asia-Pacific consensus guidelines have formalized this recommendation, advocating anabolic agents as first-line treatment for very-high-risk individuals.12PubMed. Asia-Pacific consensus on long-term and sequential therapy for osteoporosis
The reverse sequence, years of bisphosphonates followed by an anabolic drug, can blunt the anabolic response. Bisphosphonates suppress the bone remodeling machinery that anabolic drugs rely on to do their work, so by the time you switch, there is less machinery to stimulate. Combined regimens, such as denosumab plus teriparatide given together, have shown some of the largest gains in bone density in clinical trials, though this approach is not yet standard practice everywhere.13PubMed Central. Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy
Long-Term Risks of Antiresorptive Drugs
Bisphosphonates and denosumab are overwhelmingly safe for most people, but two rare complications get a lot of attention: osteonecrosis of the jaw (ONJ) and atypical femur fractures.
ONJ involves exposed, non-healing bone in the jaw, usually after dental procedures. It occurs far more often in cancer patients receiving high-dose antiresorptive therapy than in osteoporosis patients on standard doses. A large retrospective study in Taiwan found that after two years of use, the risk of ONJ was lower with denosumab than with bisphosphonates for osteoporosis patients, and the gap widened over time.14PubMed Central. Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan Risk factors that increase the likelihood of ONJ in denosumab users include concurrent chemotherapy or hormonal therapy, corticosteroid use, diabetes, periodontal disease, and poorly fitting dentures.15PubMed Central. Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab
Atypical femur fractures are stress fractures that occur along the shaft of the thighbone rather than at the hip, where typical osteoporotic fractures happen. They are linked to prolonged bisphosphonate use. In a study of nearly 200,000 women, the risk of atypical fracture rose steeply with longer use: the hazard was more than 40 times higher in women who had used bisphosphonates for eight or more years compared with those who used them for less than three months. Importantly, the risk dropped rapidly after the drug was stopped.16PubMed Central. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates The underlying mechanism appears to involve a duration-dependent increase in bone mineral density that actually makes the bone more brittle, with the drug accumulating along osteocyte walls and potentially impairing the cells’ ability to respond to mechanical strain.17PubMed. Duration-Dependent Increase of Human Bone Matrix Mineralization in Long-Term Bisphosphonate Users with Atypical Femur Fracture
This is why clinicians often recommend a “drug holiday” after three to five years of bisphosphonate therapy for patients at moderate risk. Many more typical fractures are prevented by bisphosphonates than atypical fractures are caused by them, but the balance shifts with very long-term use.18The Journal of Clinical Endocrinology & Metabolism. Benefits and Risks of Bisphosphonate Therapy for Osteoporosis
The Denosumab Rebound Problem
Unlike bisphosphonates, denosumab does not linger in bone. Once you stop it, osteoclast numbers and activity surge above pre-treatment levels in what researchers call the rebound phenomenon. Bone turnover spikes, bone density drops rapidly, and a minority of patients develop multiple vertebral fractures, sometimes within three to twelve months of their last dose.19PubMed Central. Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review These rebound-associated vertebral fractures are distinct from atypical femur fractures; they originate from a burst of bone resorption concentrated in the trabecular (spongy) bone of the spine, whereas atypical femur fractures stem from impaired repair in cortical (dense) bone during prolonged antiresorptive use.20PubMed. Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics
The practical takeaway is that you should never simply stop denosumab without a transition plan. Clinicians typically switch patients to a bisphosphonate after denosumab to dampen the rebound. This has become one of the most important messages in osteoporosis management, because the rebound risk was not widely appreciated when denosumab first came to market.
Calcium, Vitamin D, and Exercise
No medication works well on a foundation of poor nutrition or inactivity. Calcium and vitamin D supplementation is considered standard background therapy for almost everyone on osteoporosis drugs. However, the evidence for supplements on their own is more nuanced than many people assume. Vitamin D alone does not appear to reduce fracture risk. Combined calcium and vitamin D supplementation does modestly reduce fractures: meta-analyses have found roughly a 15% reduction in total fractures and a 30% reduction in hip fractures with the combination.21PubMed Central. Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation A separate large meta-analysis confirmed that combined supplementation lowered hip fracture risk by about 16%, while vitamin D alone did not.22JAMA Network Open. Vitamin D and Calcium for the Prevention of Fracture: A Systematic Review and Meta-analysis
Exercise is equally important, particularly resistance training. Bone responds to mechanical loads that exceed what you encounter in everyday life, so walking alone may not be enough.23PubMed Central. Effects of Resistance Exercise on Bone Health A network meta-analysis in postmenopausal women found that combined aerobic and resistance training ranked highest for improving bone density at both the lumbar spine and femoral neck, followed by aerobic exercise alone and resistance training alone.24Scientific Reports. Effect of different types of exercise on bone mineral density in postmenopausal women: a systematic review and network meta-analysis Progressive resistance training has also been shown to increase both muscle strength and hip bone density simultaneously, which is valuable because falls cause the fractures that osteoporosis makes devastating.25PubMed Central. Progressive Resistance Training for Concomitant Increases in Muscle Strength and Bone Mineral Density in Older Adults: A Systematic Review and Meta-Analysis
Osteoporosis Treatment in Men
Most clinical trials in osteoporosis have been conducted in postmenopausal women, and the condition is often framed as a women’s health issue. Men, however, account for a meaningful share of osteoporotic fractures, and up to 60% of men with osteoporosis have an identifiable secondary cause of bone loss, such as glucocorticoid use, low testosterone, excess alcohol, or other chronic diseases.26PubMed. Male osteoporosis-what are the causes, diagnostic challenges, and management Because most drug trials in men used bone density rather than fracture reduction as their primary outcome, the anti-fracture evidence is weaker than in women. Still, current guidance recommends treating men at high fracture risk, typically with bisphosphonates or denosumab as first-line options, and considering anabolic therapy for those at very high risk.27PubMed. Osteoporosis in Older Men: Informing Patient Management and Improving Health-Related Outcomes Denosumab is especially useful in men on androgen deprivation therapy for prostate cancer, because that treatment accelerates bone loss significantly.28PubMed. Osteoporosis in Older Men: Informing Patient Management and Improving Health-Related Outcomes
Glucocorticoid-Induced Osteoporosis
Long-term use of glucocorticoids like prednisone is one of the most common causes of secondary osteoporosis. These drugs attack bone from multiple angles: they suppress the cells that build bone, transiently stimulate the cells that break it down, weaken muscle, and disrupt calcium metabolism.29The Lancet Diabetes & Endocrinology. Glucocorticoid-induced osteoporosis: pathogenesis, diagnosis, and management The result is rapid bone loss, particularly in the first months of therapy, with fractures sometimes occurring at bone density levels that would not normally be considered high-risk.
Fracture risk assessment should happen as soon as long-term glucocorticoid therapy, typically three months or more, is initiated. Standard risk calculators may underestimate fracture risk in these patients, particularly if vertebral fractures are already present. Bisphosphonates are generally considered first-line treatment on cost grounds, but anabolic therapy is increasingly viewed as an appropriate first-line alternative for very-high-risk individuals on glucocorticoids. Calcium and vitamin D supplementation should accompany any bone-protective therapy.30PubMed. Extensive expertise in endocrinology: advances in the management of glucocorticoid-induced osteoporosis
Why Sticking With Treatment Matters More Than People Think
Osteoporosis drugs only work if you take them. This sounds obvious, but adherence rates in real-world practice are poor. Many people stop their medication within the first year, often because they feel fine and do not perceive an immediate benefit. The consequences are measurable: a meta-analysis found that non-adherence increases fracture risk by roughly 30%, and stopping treatment entirely raises it by 30 to 40%.31PubMed. A meta-analysis of osteoporotic fracture risk with medication nonadherence Among U.S. Medicare patients who had already suffered a fragility fracture, those with low medication adherence were about a third more likely to fracture again compared with highly adherent patients.32PubMed Central. Examining the Effect of Medication Adherence on Risk of Subsequent Fracture Among Women with a Fragility Fracture in the U.S. Medicare Population
Switching from daily or weekly oral pills to less frequent dosing, such as six-monthly denosumab injections or yearly zoledronic acid infusions, is one strategy that can help. Clear communication about why the drug is necessary even when you feel well is another. The fracture you are trying to prevent, a broken hip, a crushed vertebra, carries consequences that far outweigh the inconvenience of the treatment.
How Bone Density Is Tracked
Dual-energy X-ray absorptiometry (DXA) remains the gold standard for diagnosing osteoporosis and monitoring treatment response. It measures bone mineral density at the spine and hip, and the results are used both to classify the severity of bone loss and to estimate future fracture risk.33PubMed Central. Updates on the Role of DXA in the Evaluation and Monitoring of Osteoporosis DXA results feed into the FRAX tool, a widely used calculator that combines bone density with clinical risk factors like age, weight, smoking, and family history to estimate the 10-year probability of a major osteoporotic fracture or hip fracture.34PubMed Central. An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis Clinicians often use these FRAX thresholds to decide when to start treatment, when to switch drugs, and when a drug holiday might be appropriate.
Cathepsin K Inhibitors and the Research Pipeline
One of the more intriguing drug targets that researchers have pursued is cathepsin K, the enzyme that osteoclasts use to break down bone collagen. Blocking this enzyme reduces resorption while largely sparing bone formation, a profile that pharmacologists found very appealing.35PubMed Central. Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis The leading candidate, odanacatib, went through a large phase III trial and did reduce fractures at multiple skeletal sites. However, it was ultimately pulled from regulatory review after an increased risk of stroke was identified.36PubMed Central. Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned
No cathepsin K inhibitor has achieved approval, and the off-target effects of blocking cathepsin activity outside of bone, including in blood vessels and skin, remain a challenge.37PubMed Central. Review of Cathepsin K Inhibitor Development and the Potential Role of Phytochemicals The concept itself, an antiresorptive that does not suppress formation, is still considered scientifically valid. Researchers continue to look for safer ways to achieve it, including plant-derived compounds, though none are near clinical use.
The Gut Microbiome Connection
A more speculative but rapidly growing area of research involves the gut microbiome. Studies have found that gut bacteria influence bone metabolism through several pathways: they affect calcium and nutrient absorption, they modulate immune cells involved in osteoclast regulation, and they may influence bone turnover through signaling molecules like short-chain fatty acids and serotonin.38PubMed Central. Gut Microbiome and Osteoporosis In animal models, modifying gut bacteria has increased bone mass by suppressing osteoclast activity or promoting osteoblast maturation. Whether probiotic or prebiotic interventions will translate into meaningful fracture prevention in humans is still unknown. For now, a healthy and varied diet likely supports both gut health and bone health, but no specific microbiome-targeted therapy for osteoporosis is ready for clinical use.